Kadmon Holdings Llc (KDMN)

Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.

Company Info

Kadmon Holdings Llc

450 E 29th St

New York City NEW YORK 10016

P: 18339005366.0

CEO: Harlan W. Waksal

Employees: 0

Website: http://kadmon.com/